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KIT is a member of the tyrosine kinase family of growth factor receptors which is expressed on a variety of haematopoietic cells
including mast cells. Stem cell factor (SCF)-dependent activation of KIT is critical for mast cell homeostasis and function.
However, when KIT is inappropriately activated, accumulation of mast cells in tissues results in mastocytosis. Such dysregulated
KIT activation is a manifestation of specific activating point mutations within KIT, with the human D816V mutation considered
as a hallmark of human systemic mastocytosis. A number of other activating mutations in KIT have recently been identified and
these mutations may also contribute to aberrant mast cell growth. In addition to its role in mast cell growth, differentiation and
survival, localized concentration gradients of SCF may control the targeting of mast cells to specific tissues and, once resident
within these tissues, mast cell activation by antigen may also be amplified by SCF. Thus, KIT inhibitors may have potential
application in multiple conditions linked to mast cells including systemic mastocytosis, anaphylaxis, and asthma. In this review,
we discuss the role of KIT in the context of mast cells in these disease states and how recent advances in the development of
inhibitors of KIT activity and function may offer novel therapies for the treatment of these disorders.
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Introduction
The human c-KIT oncogene, which is mapped to the W locus
in the mouse, encodes for a protein, KIT (CD117), which is a
member of the transmembrane receptors with tyrosine
kinase activity superfamily. This family also includes other
growth factor receptors, namely FMS-like tyrosine kinase 3
(FLT3), the platelet-derived growth factor receptor (PDGFR),
and the macrophage colony stimulating factor (M-CSF)
receptor (Broudy, 1997; Patnaik et al., 2007). Expression of
human KIT is primarily restricted to melanocytes, germ cells
and cells of haematopoietic lineage, including bone marrow
progenitor cells, mast cells, megakaryocytes (Kitamura et al.,
1995, 2006; Roskoski, 2005a, b; Alexeev and Yoon, 2006)
and, to a lesser extent, basophils and eosinophils (Yuan et al.,
1997; Heinemann et al., 2005). It has also been reported to be
expressed in other cell types such as epithelial cells and
vascular smooth muscle cells (Al-Muhsen et al., 2004;
Hollenbeck et al., 2004). KIT is expressed as several
alternatively spliced isoforms, which, following glycosyla-
tion, give rise to proteins with multiple molecular weights
around 145 kDa (Yarden et al., 1987). The ligand for KIT,
stem cell factor (SCF), also known as steel factor based on
its generation by the Steel locus (Sl) in mouse (Yarden et al.,
1987; Huang et al., 1990), exists in two forms that are
produced by alternative splicing: a soluble form of approxi-
mately 31 kDa and a membrane-bound form of approxi-
mately 32 kDa, which lacks the proteolytic site for processing
into the soluble form (Flanagan and Leder, 1990). In both
human and mouse, there is evidence that KIT may respond
differentially to these individual forms of SCF (Toksoz et al.,
1992; Kapur et al., 1998; Trieselmann et al., 2003). SCF is
expressed in fibroblasts, thymus tissue, spleen, testes,
placenta and mast cells (reviewed by Broudy, 1997; Reber
et al., 2006) and, under normal conditions, in humans it is
present in the plasma at concentrations of approximately
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1–3 ng mL1 (B0.2 nM) (Kojima et al., 1997). However, local
concentrations near the sites of origin and localized
membrane-associated KIT concentrations are likely to be
significantly higher.
KIT has five immunoglobulin-like regions within its
extracellular domain that contain the binding site for SCF
(Figure 1). The Kd for the binding of SCF to human KIT is
reported to be 4.2 pM for high-affinity binding and 1.7 nM for
lower-affinity binding (Broudy et al., 1994). Thus, reasonable
increases in localized concentrations of SCF would be
sufficient for optimal activation of the receptor. As with
other receptors with tyrosine kinase activity, KIT-mediated
cellular responses follow ligand-induced dimerization of the
receptor and resulting activation of its inherent tyrosine
kinase activity. This activity is associated with a split catalytic
domain contained within its cytosolic domain (Mol et al.,
2003) (Figure 1). The KIT kinase activity targets specific
tyrosine residues also contained within the cytosolic domain
of KIT. Thus, once ligated, KIT undergoes auto/transpho-
sphorylation (Mol et al., 2003). The Src kinase, Lyn, may also
contribute to phosphorylation of specific sites within KIT
(Shivakrupa and Linnekin, 2005). Following phosphoryla-
tion, sequences containing these phosphotyrosines become
docking sites for associating critical signalling molecules.
These molecules include the Src kinases Lyn and Fyn,
phospholipase Cg, phosphoinositide 3-kinase (PI3K) and
the adaptor molecules Grb2 and Shc (Lev et al., 1992; Serve
et al., 1994; Herbst et al., 1995; Linnekin et al., 1997; Price
et al., 1997; Thommes et al., 1999; Gilfillan and Tkaczyk,
2006; Samayawardhena et al., 2006) (Figure 2). The specific
residues responsible for these interactions have been mapped
by site-directed mutagenesis, revealing that, in the case of
human KIT, phospholipase Cg binds to pY936 (Herbst et al.,
1995), PI3K to pY721 (Herbst et al., 1995), Grb2 to pY703 and
pY936 (Herbst et al., 1995; Thommes et al., 1999), and Lyn
and Fyn to pY568 and pY570 (Linnekin et al., 1997;
Samayawardhena et al., 2006). By recruiting these molecules,
a receptor-signalling molecule complex is established which
coordinates the critical downstream signalling events
leading to the diverse cellular responses attributable to KIT.
Also recruited are a number of signalling molecules whose
function is to terminate an ongoing reaction. These include
the phosphoinositide phosphatase SHIP (van Dijk et al.,
2000), which reverses the actions of PI3K, the protein
phosphatase SHP1 (Kozlowski et al., 1998), which reverses
the phosphorylation events initiated by KIT, the tyrosine
kinase Chk (Price et al., 1997), which inactivates Src kinases,
and SOCS6 (Bayle et al., 2004), which downregulates
signalling pathways leading to cytokine gene expression.
As it is not the purpose of this review to discuss in length
the downstream signalling processes that account for the
biological responses mediated by KIT, readers are referred to
several excellent reviews that contain in-depth discussions of
these events (Broudy, 1997; Linnekin, 1999; Lennartsson
et al., 2005; Roskoski, 2005a, b; Reber et al., 2006) and to
Figure 2, which summarizes these process.
Roles of KIT and normal and dysregulated control
of mast cell function
Stem cell factor-dependent ligation of KIT, and the subse-
quent activation of KIT kinase activity, is essential for mast
cell homeostasis. Mice that are defective for functional KIT
expression (W/Wv and W/Wsh) (Kitamura et al., 1978) and
those defective for SCF (Sl/Sld) (Kitamura and Go, 1979) are
thus mast cell deficient. In humans, expansion and differ-
entiation of mast cells from their CD34þ /CD117þ progeni-
tor cells is also dependent on SCF, as demonstrated in ex vivo
culture systems (Kirshenbaum et al., 1999). Once mature, the
continued survival of human mast cells is also dependent on
the presence of SCF, as cells deprived of SCF display signs of
apoptosis within 24–48 h (Metcalfe et al., 1995). A number of
activating mutations in KIT are associated with the dysregu-
lated growth of mast cells associated with mastocytosis (Akin
and Metcalfe, 2004). These activating mutations will be
discussed later. Under experimental conditions, in vitro, SCF
has been demonstrated to be a potent chemotactic agent for
mast cells (Nilsson et al., 1994; Dastych et al., 1998) and mast
cell precursors (Taylor et al., 2001), and to induce mast cell
adhesion to basement membrane proteins (Dastych and
Metcalfe, 1994; Lorentz et al., 2002). Thus, in vivo, in
addition to its role in mast cell homeostasis, SCF likely
contributes to the processes that regulate the homing of
mast cells to their sites of residence within tissues/organs
such as skin, intestinal mucosa and submucosa, alveolar
walls, nasal mucosa, bronchial subepithelium and tonsils
(Okayama and Kawakami, 2006). However, the extent to
which SCF contributes to this process in vivo is currently
unknown.
In addition to its ability to regulate mast cell homeostasis
and tissue distribution, SCF is also recognized as a potent
modifier of mast cell activation. When triggered, mast cells
release an array of inflammatory mediators that contribute
to the initiation of anaphylaxis and the inflammatory
reactions associated with the asthmatic response (Metcalfe
et al., 1997). These mediators include granule-associated
bioactive amines such as histamine and 5-hydroxytrypta-
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Figure 1 Structure of human KIT and selected mutations associated
with specific human disease states.
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leukotriene C4, chemokines such as CCL2, CCL3, CCL5 and
cytokines such as tumour necrosis factor-a (TNF-a), granu-
locyte macrophage colony-stimulating factor, interleukins
(ILs) 3, 4, 5, 6, 10 (Galli et al., 2005; Gilfillan and Tkaczyk,
2006). These events generally occur following antigen-
dependent aggregation of IgE-occupied high-affinity recep-
tors for IgE (FceRI) on the mast cell surface (Metcalfe et al.,
1997; Galli et al., 2005; Rivera and Gilfillan, 2006; Tkaczyk
et al., 2006). FceRI-mediated mast cell activation, however,
can be dramatically enhanced by the concurrent activation
of other receptors on mast cells, including KIT, and those for
adenosine, sphingosine-1-phosphate, complement compo-
nent C3a, PGE2 and lysophosphatidic acid (Gilfillan and
Tkaczyk, 2006; Kuehn and Gilfillan, 2007), although, in
cultured human mast cells, adenosine and PGE2 can also
inhibit antigen-induced mast cell degranulation (Kuehn and
Gilfillan, 2007). Owing to its unique influence on mast
cell homeostasis (Kitamura et al., 2006), however, of these
receptors, KIT is likely the major modifier of antigen-
mediated mast cell responses in a physiological setting.
The evidence supporting the role of KIT as a co-activator of
mast cells, however, has primarily emerged from studies
conducted in both rodent and human mast cell cultures
where it has been demonstrated that the threshold for
antigen-mediated degranulation is lowered and the magni-
tude of this response is synergistically enhanced by SCF
(Gilfillan and Tkaczyk, 2006). These studies have also
demonstrated that antigen-mediated cytokine production
in mast cells is also dramatically enhanced by SCF. Thus, as
with the role of KIT on mast cell homing, the precise
contribution of KIT activation on mast cell activation in vivo
has yet to be determined.
KIT and mast cell disorders
Although KIT is a critical molecule in haematopoesis,
gametogenesis, and mast cell development, activating
mutations resulting in ligand-independent autophosphory-
lation may lead to dysregulated growth of the affected cells,
thereby inducing tumourogenesis (Akin and Metcalfe, 2004).
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Figure 2 Binding of specific signalling proteins to phosphorylated tyrosine residues on KIT following receptor activation and the subsequent
signalling events leading to mast cell responses. For clarity, only one receptor is shown in the figure. SCF-induced KIT dimerization enhances
the tyrosine kinase activity associated with the split catalytic domain. This results in phosphorylation of specific tyrosine residues within the
cytosolic domain of KIT. The tyrosine kinase, Lyn, may also contribute to this response. The consequential recruitment of critical signalling
molecules such as the tyrosine kinases, Lyn and Fyn, the adaptor molecules, SHC and Grb2 and the signalling enzymes, PI3K and
phospholipase Cg, results in the activation of the Ras–Raf–mitogen-activated protein kinase (MAPK) pathway, the enhancement of intracellular
calcium levels, and the activation of transcription factors leading to mast cell growth, differentiation and survival; enhanced cell migration and
chemotaxis; and cytokine production. Activation of the JAK2 and STAT1/3/5 likely contributes to these responses. Concurrent with these
events, KIT induces activation of the Tec kinase Btk and the adaptor molecule NTAL (non-T-cell activation linker), resulting in an enhancement
of antigen-mediated degranulation and cytokine production. (For further details, please refer to Broudy, 1997; Linnekin, 1999; Tkaczyk et al.,
2004; Iwaki et al., 2005; Lennartsson et al., 2005; Roskoski, 2005a, b; Gilfillan and Tkaczyk, 2006; Reber et al., 2006.)
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mastocytosis, germ cell tumours and core factor binding
acute myeloid leukaemias carry mutations in KIT (Patnaik
et al., 2007). However, in terms of mast cell disorders, the two
principal conditions where aberrant KIT activation may play
a role are mastocytosis and anaphylaxis.
Mastocytosis
Pathologic constitutive activation of KIT is associated with
the mast cell proliferative disorder, mastocytosis (Valent
et al., 2001, 2003b), as originally described by Nagata et al.
(1995). More than 90% of patients with systemic masto-
cytosis have the D816V KIT point mutation, resulting in
SCF-independent autophosphorylation (Akin, 2006; Garcia-
Montero et al., 2006). The aspartic acid produced by Codon
816 of KIT is located in the tyrosine kinase domain and is
critically involved in ATP binding and subsequent phospho-
transferase activity of the receptor (Mol et al., 2003;
Vendome et al., 2005). Mutations resulting in replacement
of this aspartic acid with valine stabilize the kinase in its
active conformation (Mol et al., 2004; Vendome et al., 2005),
thus obviating the need for binding SCF for autopho-
sphorylation (Furitsu et al., 1993). Although D816V is by
far the most common mutation detected in mastocytosis,
mutations involving other KIT domains (such as in the
juxtamembrane, transmembrane and extracellular regions)
have also been described (Figure 1).
The exact role of D816V KIT in pathogenesis of masto-
cytosis remains to be identified. In vitro studies showed that
D816V KIT was able to confer growth factor independence to
transformed haematopoietic cell lines (Kitayama et al., 1995)
as well as murine haematopietic progenitor cells (Kitayama
et al., 1996). Human mast cells carrying D816V KIT were
more resistant to apoptosis induced by SCF withdrawal (Akin
et al., 2003) and migrated more vigorously to SCF (Taylor
et al., 2004). Animal studies showed some, but not all (8 out
of 28), transgenic mice carrying D816V c-KIT mutation
under the control of chymase promoter develop a disease
state resembling mastocytosis with infiltration of tissues
such as skin and spleen (Zappulla et al., 2005). On the other
hand, mice transplanted with haematopoietic stem cells
retrovirally transduced with D814V KIT, as well as mice
transgenic for this mutation, develop acute leukaemias and
lymphomas but not mastocytosis (Kitayama et al., 1996). In
humans, activating KIT mutations are seen not only in
mastocytosis, but also in core factor binding acute leukae-
mias (Beghini et al., 2000), gastrointestinal stromal tumours
(Hirota et al., 1998), germ cell tumours (Tian et al., 1999) and
some lymphoproliferative disorders (Hongyo et al., 2000).
The presence of KIT mutations do not appear to correlate
with aggressiveness or prognosis of mastocytosis in humans.
Overall, these observations suggest that, although KIT
mutations (particularly D816V) are important pathogenic
factors in mastocytosis, additional mutations or polymorphisms
are needed to determine the final disease phenotype.
Anaphylaxis
In addition to a role for KIT mutations in the development
of mastocytosis, it has been proposed that there is a link
between aberrant KIT activation and anaphylaxis, although
this conclusion is somewhat more controversial. Certainly,
based on in vitro studies, it would be logical to assume that an
activating mutation in KIT would result in exaggerated
antigen-mediated mast cell activation. Surprisingly, one
study using mismatch amplification real-time PCR assay
found a relatively high occurrence of the D816V mutation (2
out of 9, 22%) in subjects without a history of atopy or
anaphylaxis (Lawley et al., 2005). The same study identified
the mutation in 9 out of 21 (43%) patients with anaphylaxis,
although this apparently increased detection rate in anaphy-
laxis was not statistically significant (Lawley et al., 2005).
Mice receiving chronic treatment of SCF do not have an
increase in IgE-dependent anaphylaxis (Ando et al., 1993). In
contrast, there is evidence suggesting that the SCF–KIT axis is
important in the development of non-IgE-dependent ana-
phylaxis. Anaphylactic-type dermal mast cell degranulation
was observed in patients with advanced breast cancer who
received subcutaneous injections of SCF in a Phase 1 clinical
trial (Costa et al., 1996). More recently, the D816V c-KIT
mutation and other markers of clonal mast cell disease such
as aberrant surface expression of CD25 by mast cells have
been reported in a subgroup of patients with recurrent
idiopathic anaphylaxis (Akin et al., 2007). Some of these
patients had a mild increase in mast cell numbers in bone
marrow, which did not meet the diagnostic criteria for
systemic mastocytosis. Such patients who experience ana-
phylaxis and carry a population of clonal mast cells without
meeting the diagnostic criteria for systemic mastocytosis
have been termed to have a monoclonal mast cell activation
syndrome (Florian et al., 2005; Akin et al., 2007).
The multiple roles that SCF and KIT may play in
dysregulated mast cell homeostasis and activation therefore
provide a basis for considering inhibitors of KIT activity and
function in the treatment of a number of mast cell related
disorders including mastocytosis, atopic asthma, and ana-
phylaxis.
Pharmacological targeting of KIT
It is clear from mutational analysis and from studies
conducted in knock out mice that KIT-induced phosphory-
lation of the tyrosines contained within the cytosolic tail
and the subsequent recruitment of signalling molecules are
essential events for the biological function of KIT (Broudy,
1997; Linnekin, 1999; Roskoski, 2005a, b; Akin et al., 2007).
Thus, pharmacological targeting of these processes, espe-
cially the KIT catalytic activity, has been a major strategy for
blocking KIT-mediated responses. In the following sections,
we will discuss the pharmacology of KIT inhibitors and how
the disease states discussed above may be suitable target for
potential targeting with KIT inhibitors.
The various tyrosine kinase inhibitors that have been
described to inhibit KIT activity are listed in Table 1. The
most widely recognized compound that blocks KIT catalytic
activity is imatinib mesylate (imatinib) (also known as
STI571, Gleevec and Glivec). Imatinib targets KIT at the
ATP-binding site, thereby maintaining the receptor in a non-
activated state. It is relatively selective as, in addition to KIT,
The KIT tyrosine kinase growth factor receptor
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it has been reported to inhibit only Bcr-Abl and the PDGFR.
This may explain why imatinib induces relatively few side
effects and is well tolerated (Levitzki and Mishani, 2006).
Imatinib targets not only wild-type KIT but also KIT carrying
the V560G mutation (Heinrich et al., 2000). However, KIT
carrying the D816V mutation associated with systemic
mastocytosis is resistant to imatinib inhibition, due to the
mutation changing the ATP binding site configuration,
thereby blocking the binding of imatinib to KIT (Scheinfeld,
2006). Thus, although imatinib can prevent the growth of
human mast cells that express wild-type KIT, the dysregu-
lated growth of tumour mast cells linked to the D816V
mutation is resistant to imatinib treatment (Zermati et al.,
2003). A similar pharmacological profile has been reported
for the imatinib mimetics, nilotinib (AMN107) and
PD180970, which can inhibit both wild-type KIT and KIT
carrying the V560G mutation, but not KIT containing the
D816V mutation (Corbin et al., 2004; Verstovsek et al.,
2006a; Chow et al., 2007). Nilotinib, in addition to targeting,
KIT, Bcr-Abl and the PDGFR, has also been described to be
cytotoxic to B cells, due to caspase activation, independently
of kinase inhibition (Gleixner et al., 2006). Besides KIT,
PD180970 has been described to inhibit only Bcr-Abl and Src
(Dorsey et al., 2000). There has therefore been a focus on the
development of KIT kinase inhibitors that overcome the
drug-resistance associated with the D816V mutation.
Recently, several compounds have been identified that
inhibit the catalytic activity associated with KIT carrying the
D816V mutation. These include dasatinib (BMS-354825),
midostaurin (PKC412, N-benzoyl-staurosporine), hypothe-
mycin, EXEL-0862, MLN518, AP23646/AP23848 and
semaxinib (SU5416). These compounds are all multikinase
inhibitors and therefore less specific than imatinib, nilotinib
and PD18070. Dasatinib inhibits the growth of both human
mast cell line (HMC)-1.1 and HMC-1.2 human mast cell
lines, which express the V560G mutation or the V560G and
V816D mutations, respectively. The growth inhibitory effect
correlates with the compound’s inhibitory effect on KIT
autophosphorylation found in both of these cell lines (Shah
et al., 2006; Gleixner et al., 2007). Dasatinib has also been
reported to cooperate with midostaurin, nilotinib, imatinib
and 2CdA (2-chloro-deoxy-adenosine) to produce an en-
hanced inhibition of growth, and the induction of apoptosis,
of neoplastic mast cells (Gleixner et al., 2007). In addition to
KIT inhibition, however, dasatinib is also described to target
Src kinases and the related Tec kinases Bruton’s tyrosine
kinase (Btk) and Tec. These properties would explain the
reported ability of dasatinib to block histamine release from
mast cells and basophils (Hantschel et al., 2007): a process
dependent on the activation of both Src kinases and Btk
(Gilfillan and Tkaczyk, 2006). Midostaurin has a broad
antiproliferative activity against various normal and tumour
cell lines, including HMC-1.1 and HMC-1.2 cells, where it is
also associated with induction of apoptosis (Fabbro et al.,
2000; Gleixner et al., 2006). The many different cell types
affected by midostaurin may be due to its several targets
besides KIT, as this protein kinase inhibitor also targets PKC,
FLT3, vascular endothelial growth factor receptor (VEGFR)-2,
PDGFR and FGFR (Fabbro et al., 2000).
In addition to inhibiting wild-type and D816V KIT,
hypothemycin has also been described to inhibit other
protein kinases with a conserved cysteine in the ATP-binding
Table 1 KIT inhibitors and their targets
Inhibitor Additional names Kit target Additional targets Reference
Imatinib Gleevec Wild type, V560G Bcr-Abl, PDGFR (Jensen et al., 2007)
Glivec (Levitzki et al., 2006)
STI571 (Ma et al., 2002)
Nilotinib AMN107 Wild type, V560G Bcr-Abl, PDGFR (Chow et al., 2007)
(Gleixner et al., 2006)
PD180970 Wild type, V560G Bcr-Abl, Src (Corbin et al., 2004)
(Roskoski, 2005a, b)
Dasatinib BMS-354825 Wild type, V560G, D816V Src kinases, Tec, Btk (Shah et al., 2006)
(Gleixner et al., 2007)
(Hantschel et al., 2007)
Midostaurin PKC412 Wild type, V560G, D816V PKC, FLT3, VEGFR2, (Patnaik et al., 2007)
N-benzoyl-staurosporine PDGFR, FGFR (Fabbro et al., 2000)
(Gleixner et al., 2006)
Hypothemycin Wild type, D816V a (Schirmer et al., 2006)
EXEL-0862 Wild type, D816V STAT3 (Pan et al., 2007)
MLN518 Wild type, D816V STAT3 (Corbin et al., 2004)
AP23646/AP23848 Wild type, D816V STAT3, Akt, ERK (Patnaik et al., 2007)
Semaxinib SU5416 Wild type, D816V STAT3, Akt, ERK (Kosmider et al., 2007)
Sunitinib SU11248 Wild type, V559D, V645A, VEGFR, PDGFR, FLT3 (Chow et al., 2007)
V559D/T670I, V670I (Prenen et al., 2006)
Sorafenib BAY 43-9006, Nexavar Wild type VEGFR 2,3, PDGFR, FLT3, (Liu et al., 2006)
Raf, MEK, ERK
Pazapanib GW786034 Wild type VEGFR 1,3, PDGFRa,b (Sonpavde and Hutson, 2007)
17-AAG Wild type HSP90, Akt, STAT3 (Ramanathan et al., 2005)
(Fumo et al., 2004)
MD-0354 V560G, D816V NFkB (Tanaka et al., 2005)
aPKs with a conserved cysteine in the ATP-binding site.
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site. These include several of the mitogen-activated protein
kinases (Schirmer et al., 2006). Studies conducted in mast
cells also suggest that hypothemycin can inhibit an up-
stream regulator of Btk (Jensen et al., 2008); however,
hypothemycin does not appear to inhibit Btk directly as
assessed in an in vitro kinase assay (Schirmer et al., 2006). The
ability of hypothemycin to inhibit the activation of Btk in
mast cells would again account for the ability of the
compound to inhibit antigen-induced and KIT-enhanced
mast cell degranulation and cytokine production (Jensen
et al., 2008). EXEL-0862, MLN518 AP23646/AP23848 and
semaxinib have been reported to inhibit STAT3 phosphor-
ylation in addition to their effects on wild-type and D816V
KIT (Corbin et al., 2004; Kosmider et al., 2007; Pan et al.,
2007; Patnaik et al., 2007). Furthermore, AP23646/AP23848
and semaxinib have also been shown to affect Akt and ERK
activities (Kosmider et al., 2007; Patnaik et al., 2007).
Certain VEGFR inhibitors have been found to also target
KIT; however, their ability to inhibit KIT containing the
D816V mutation is unreported. Sunitinib (SU11248), for
example, inhibits VEGFR, PDGFR, KIT, FLT3 and has been
reported to inhibit KIT containing V559D and V559D/T670I
mutations in systemic mastocytosis and imatinib-resistant
KIT mutations in gastrointestinal stromal tumours (V645A
and T670I) (Prenen et al., 2006; Chow and Eckhardt, 2007;
Patnaik et al., 2007). Sorafenib (BAY 43-9006, Nexavar),
which targets VEGFR2þ3, PDGFR, FLT3 and Raf (Liu et al.,
2006), inhibits MAPK/ERK kinase and ERK phosphorylation
and downregulates the anti-apoptotic protein Mcl-1 in an
MAPK/ERK kinase/ERK independent way and also has been
demonstrated to inhibit wild-type KIT. Furthermore, pazo-
panib (GW786034), which targets VEGFR1, 2 and 3 and
PDGFR-a and PDGFR-b, also inhibits wild-type KIT (Sonpavde
and Hutson, 2007).
A number of compounds, not primarily considered to be
tyrosine kinase inhibitors, have also been reported to inhibit
KIT activity or KIT-mediated responses in mast cells. These
include the following: (1) The anti-tumour antibiotic 17-
allylamino-17-demethoxygeldanamycin, which, in addition
to targeting the cytocolic heat shock protein 90 (Rama-
nathan et al., 2005), was also reported to decrease the
phosphorylation of KIT, Akt and STAT3 in both HMC-1
subclones (Fumo et al., 2004); (2) IMD-0354, an nuclear
factor-kB inhibitor that has been shown to suppress
proliferation of the subtype HMC-1.2 cells but not in cord
blood-derived human mast cells expressing wild-type KIT
(Tanaka et al., 2005). HMC-1.2 cells have constitutively
activated nuclear factor-kB, which mediates upregulation of
cyclin D3, resulting in cell cycle progression. Targeting
nuclear factor-kB and inhibiting its activation pathway
therefore results in suppression of cell proliferation; (3)
Rapamycin targets the serine/threonine protein kinase
mTOR, which is activated by KIT in a PI3K-dependent
manner in mast cells (Kim et al., 2008). The mTOR pathways
is critical for optimal mast cell growth, and tumour mast
cells expressing the V560G or D816V mutation have
constitutively activated mTOR. Rapamycin has been re-
ported to only induce apoptosis in cells carrying D816V
mutation, but not in V560G-mutated cells or wild-type mast
cells (Gabillot-Carre et al., 2006). However, in a later study,
rapamycin was reported to inhibit mast cell growth/survival,
irrespective of the presence of a specific mutation (Kim et al.,
2008). These results are somewhat in contrast with imatinib,
which only affects wild type and mast cells expressing
V569G KIT.
The potential use of KIT inhibitors in the treatment
of systemic mastocytosis
Cytoreductive therapy of systemic mastocytosis is generally
reserved for patients with advanced forms of mastocytosis
associated with decreased life expectancy (Valent et al.,
2003a). This is because of the concerns about potential
mutagenicity, teratogenicity and lack of knowledge about
the long-term toxicity of tyrosine kinase inhibitors. Inhibi-
tion of KIT as a potential cytoreductive approach in mast cell
disease is based on several lines of evidence, perhaps the
strongest of which is the high (greater than 90%) detection
rate of the presence of the activating D816V KIT mutation
in mastocytosis. Transfection of this mutation in haemato-
poietic cells renders growth factor independence (Kitayama
et al., 1995, 1996), thereby confirming the role of the
mutation in neoplastic transformation. Moreover, there is a
strong correlation between the ability of a given compound
to inhibit KIT autophosphorylation and its cytotoxic effects
on mast cell lines. Ex vivo experiments performed with
mononuclear cells obtained from the bone marrow of
patients with systemic mastocytosis showed that tyrosine
kinase inhibitors effective against D816V KIT cause prefer-
ential cytotoxicity of mast cells carrying this mutation over
other mononuclear cells (Akin et al., 2003; Shah et al., 2006).
On the other hand, it is not known whether neoplastic mast
cells have other survival pathways in addition to KIT. This is
especially plausible in patients with advanced forms of
mastocytosis such as aggressive systemic mastocytosis.
Moreover, the concentrations required to inhibit mast cell
growth may be difficult to achieve in vivo without toxicity to
other tissues. This problem may be particularly pertinent for
non-specific inhibitors with multiple targets.
The proof of concept that a KIT inhibitor can indeed cause
regression of mastocytosis driven by a KIT mutation resulted
from a study in which a patient with an unusual activating
KIT mutation was treated with imatinib, and achieved
complete remission (Akin et al., 2004). This patient had a
transmembrane mutation involving codon 522 (F522C),
which was sensitive to imatinib. Treatment of the patient
with imatinib doses up to 400 mg day1 resulted in a
dramatic decrease in serum levels of the mast cell marker,
tryptase, and mast cell burden. Imatinib is also effective in
the treatment of rare cases of systemic mastocytosis
associated with chronic eosinophilic leukaemia, which is
characterized by the presence of the FIP1L1–PDGFRA
rearrangement (Pardanani et al., 2003a, b). This rearrange-
ment occurs due to an approximately 800 kB interstitial
deletion in chromosome 4 (detected by deletion of CHIC2
locus in 4q12 by immunofluorescence in situ hybridization
or by reverse transcription-PCR), leading to constitutive
activation of the intrinsic tyrosine kinase activity of
PDGFRA. These patients, who have a multilineage
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myeloproliferative disorder that involves mast cell as well as
eosinophil progenitors, are generally male, display organ
pathology due to eosinophilia and do not have the
characteristic D816V KIT mutation observed in other
categories of mastocytosis (Klion et al., 2003, 2004; Pardanani
et al., 2003c; Maric et al., 2007). In addition, a patient with a
rare variant of mastocytosis associated with chronic baso-
philic leukaemia and a PDGFRB fusion has been shown to
respond to imatinib (Lahortiga et al., 2008). The therapeutic
effect of imatinib in these disorders is due to its inhibition of
PDGFR and not KIT.
Imatinib is currently approved by the US Food and Drug
Administration for the indication of treatment of adult
patients with aggressive systemic mastocytosis without the
D816V c-Kit mutation or with c-Kit mutational status
unknown. The bulk of the clinical evidence forming the
basis of this recommendation appears to have come from
patients with chronic eosinophilic leukaemia associated with
systemic mastocytosis and FIP1L1–PDGFRA fusion gene as
discussed above. However, as opposed to its beneficial effects
in rare variants of systemic mastocytosis without codon
816 KIT mutations, or those with PDGFR rearrangements,
imatinib is not effective in inhibiting codon 816 KIT
mutations carried by the great majority of patients with
systemic mastocytosis (Ma et al., 2002; Akin et al., 2003;
Zermati et al., 2003). As discussed earlier, this is thought to
be due to the inability of the drug to bind the enzymatic
pocket of KIT, whose structure is altered by the point
mutation in codon 816. In apparent contrast to these
findings, a recent study on 14 patients with mastocytosis
reported a modest beneficial effect of imatinib on patients
with D816V KIT who received the drug, as measured by
decreased mast cell mediator levels, bone marrow mast cell
numbers and symptomatic improvement (Droogendijk et al.,
2006). However, imatinib in this study was administered
with glucocorticoids, complicating the interpretation of the
response to imatinib. Interestingly, imatinib has been shown
to decrease spontaneous histamine release in HMC-1.2
human leukaemic mast cells carrying the D816V mutation
(Lober et al., 2008), although it is not cytotoxic to this cell
line, which may partially explain the symptomatic improve-
ment observed in the study. However, because imatinib
preferentially inhibits wild-type KIT, long-term use of this
drug can potentially confer a growth advantage to the
neoplastic clones with D816V KIT and therefore theoretically
worsen the disease course. On the basis of in vitro data
mentioned above as well as our personal experience (Cem
Akin), our current practice is not to treat patients with codon
816 KIT mutations with imatinib.
Clinical trials with other KIT inhibitors have largely
yielded disappointing results. In a phase-2 trial of nilotinib,
among 60 patients (83% positive for D816V KIT) treated
with 400 mg twice daily dose of nilotinib, only 2 showed
complete remission (Hochhaus et al., 2006). The overall
response rate was 20% and two patients died due to disease
progression. Nausea and headaches were the most frequently
reported side effects. These results are consistent with the
lack of in vitro activity of nilotinib on D816V KIT (Verstovsek
et al., 2006a). Dasatinib has been evaluated for its therapeutic
effect on mastocytosis in a recent clinical trial. Thirty
patients with systemic mastocytosis received dasatinib at a
dose of 70 mg twice daily (Verstovsek et al., 2006b). There
were two complete remissions, both observed in patients
without D816V KIT mutation and low tryptase levels. There
was a high incidence of systemic toxicity: the drug was
stopped in 10 patients and dose reductions were necessary in
12. Six patients developed pleural effusions. These results
may be due to the non-specific targeting of KIT by dasatinib,
resulting in toxicity in concentrations required to inhibit
D816V KIT.
An ongoing clinical trial with midostaurine (100 mg twice
daily) has yielded more promising results in an interim
analysis (Gotlib et al., 2007). Eleven of 15 (73%) patients
with advanced systemic mastocytosis have shown a re-
sponse. Although there were no complete remissions, 5
patients displayed a major response and 6 had a partial
response. Nausea and vomiting were the most frequently
observed non-haematologic side effects. Midostaurine has
also shown a partial, although temporary, mast cell cyto-
reductive effect in a patient with mast cell leukaemia with
associated myelodysplasia (Gotlib et al., 2005).
Combination therapy of mastocytosis with regimens
incorporating tyrosine kinase inhibitors is yet to be explored
in clinical trials, although in vitro data obtained so far appear
promising. Combination of dasatinib with midostaurine or
cladribine yielded synergistic effects in HMC-1.2 mast cells
carrying the D816V c-KIT mutation (Gleixner et al., 2007).
Another study employing antisense mcl-1 oligonucleotides
in combination with midostaurine similarly showed a
synergistic growth inhibition in the same cell line (Aichberger
et al., 2007).
Potential use of KIT inhibitors in other disorders
As discussed earlier, mast cells play a central role in the
allergic reactions following antigen-dependent aggregation
of IgE-occupied FceRI, a response that, at least under
experimental conditions in both mouse and human mast
cells, can be strongly potentiated by SCF-induced KIT
activation. This can occur even at antigen concentrations
that produce minimal degranulation (Tkaczyk et al., 2004).
Thus, in addition to the primary targeting of the IgE-
response as a therapeutic strategy for the treatment of
allergic reactions, as discussed in a recent review article,
targeting SCF and/or KIT in addition to FceRI may have
therapeutic relevance in the treatment of these disorders
(Jensen et al., 2007). However, use of KIT inhibitors in non-
neoplastic conditions should be contemplated in clinical
trials only after a careful consideration of risk-to-benefit ratio
of the compounds to be investigated, including demonstra-
tion that such compounds do not increase the risk for
developing secondary malignancies.
The concept of concurrent inhibition has been explored
using hypothemycin, as this molecule in both human and
mouse mast cells targets FceRI signalling in addition to KIT
(Jensen et al., 2008). In addition to its ability to block
FceRI-mediated and KIT-enhanced degranulation and
cytokine production in mast cells in culture, hypothemycin
significantly reduced in vivo passive cutaneous anaphylaxis
The KIT tyrosine kinase growth factor receptor
BM Jensen et al1578
British Journal of Pharmacology (2008) 154 1572–1582
in mice. These results demonstrate the potential of a
combined KIT/FceRI inhibition in the treatment of allergic
diseases.
Mast cells have been implicated in the pathogenesis of
rheumatoid arthritis (Malone et al., 1986, 1987; Malone and
Metcalfe, 1988), and a recent study (Juurikivi et al., 2005)
revealed that imatinib effectively induces mast cell apoptosis
and reduces TNF-a production in human synovial tissue
cultures. This could lead to attenuation of the inflammation
in arthritic joints (Juurikivi et al., 2005). Other diseases where
mast cells have been proposed to play a role may also benefit
from targeting KIT in a manner similar to that described
above, although this has yet to be investigated. Such
disorders include migraine headaches, inflammatory bowel
disease, multiple sclerosis, artherosclerosis and angiogenesis
associated with tumour progression. With regard to migraine
headaches, degranulation of rat mast cells from the dura-
mater induced by compound 48/80 was shown to result in
excitation of meningal nociceptors, which was accompanied
by phosphorylation of the intracellular proteins ERK and
c-fos, resulting in a long-lasting activation leading to the
migraine headache (Levy et al., 2007). Mast cell mediators
have also been shown to be major regulators of the severity
of inflammatory bowel disease. In this respect, histamine can
induce the smooth muscle and endothelial cell contractions,
increased vascular permeability, cytokine production and
chemotaxis of inflammatory cells associated with this
condition (Fogel et al., 2005). In addition, patients with
Crohn’s disease have also been found to have an increased
number of mast cells in the submucosal layer and muscularis
propria of the gut (Oshitani et al., 2006). Therefore,
eliminating histamine release by silencing mast cells present
in the gastrointestinal tract, in a KIT/SCF dependant way,
could contribute to a better prognosis of these conditions.
A role for mast cells in multiple sclerosis has been
suggested by their ability to be activated by the main
multiple sclerosis protein, myelin basic protein, which
results in the release of IL-8 and TNF-a. Furthermore, mast
cells appear to markedly enhance T-cell activation by cell-to-
cell contact and by TNF-a (Theoharides et al., 2007). The
ability of imatinib and hypothemycin to block antigen-
mediated IL-8 and TNF-a release from human and mouse
mast cells and to block the SCF enhancement of this
response (Jensen et al., 2008) may provide the basis for
considering KIT inhibitors in the treatment of this disease. A
role of mast cells in the progression of atherosclerosis may
be due to release of the inflammatory cytokines IL-6 and
interferon-g following mast cell activation as demonstrated
in the mouse (Sun et al., 2007). Again, as imatinib and
hypothemycin has been shown to inhibit IL-6 release from
murine bone marrow-derived mast cells (Jensen et al., 2008),
these drugs may be able to dampen the role of mast cells
in atherosclerosis. Finally, human tumours are often
surrounded by mast cells, and this infiltration is associated
with a poor prognosis (Theoharides and Conti, 2004). Using
a oncogene mouse model carrying a mutation in the gene
coding for RAS, it was shown that not only did these mice
have more mast cells in dermis before development of skin
tumours, compared with controls, but a decrease in KIT
function inhibited the progress of carcinogenesis in the skin
(Muto et al., 2007). This indicates that, even though an
increase in mast cell number exist, if the KIT response is
inhibited, a better prognosis might be obtained.
Conclusions
In summary, in this review, we have discussed how specific
mast cell disorders are linked to dysregulated control of the
kinase activity associated with KIT and how tyrosine kinase
inhibitors targeting KIT show promise in the therapeutic
management of such disease states. Future advances in the
development of more selective tyrosine kinase inhibitors
that would target both normal and mutated KIT may thus
offer hope in the effective treatment of mastocytosis and
potentially anaphylaxis, and other allergic responses.
Furthermore, the potential role of mast cells in other clinical
conditions may provide a basis for the investigation of the
efficacy of KIT inhibitors in these disorders.
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